Peter D. Parker Managing General Partner
Peter D. Parker is Managing General Partner of BioInnovation Capital. He oversees fund activities and focuses on opportunities in therapeutics, laboratory
tools, diagnostics, and devices. Peter and Johannes Fruehauf co-founded LabCentral in 2013, one
of the most prominent shared-resources organizations for launching life sciences companies in the world. Peter was a General Partner at Ampersand Capital from 1989-2006 and co-led Ampersand’s life science investment focus. Peter served as founding investor and director
in two dozen companies including; ACLARA Biosciences (IPO), Alexis (Chairman, sold to Q-biogene), CoPharma (Chairman, sold to Lonza), Cyclis Pharmaceuticals
(Chairman, sold to Arqule), Huntington Laboratories (Chairman, sold to EcoLab), Nanodyne (Chairman, sold to UmiCore), NOVEX (Chairman, sold to Invitrogen),
Panacos Pharmaceuticals (Chairman, public/reverse merger and PIPE with Vitex), Pentose Pharmaceuticals (sold to Vitex), Protein Ingredient Technologies
(Chairman, sold to Associated British Foods). He also invested in and was a Director of AC Tech,
Dynex, Magellan BioSciences,
TekCel, and Tomah Products.
Since stepping away from a full-time role at Ampersand in 2006, Peter has become one of the most important investors in the early stage life sciences network
in Cambridge/Boston. Together with Eric Linsley, Peter formed Cequent Pharmaceuticals (Cambridge, MA) which he ran with Johannes Fruehauf and Susie
Harborth until Cequent was sold to Marina Biotech (Nasdaq: MRNA) in July 2010. He was also the
seed investor and founding CEO/Chairman of Boston Heart Diagnostics in 2006, one
of the highest profile angel transactions in the U.S. Boston Heart Dx was sold in January 2015 to Eurofins S.A.
Governor Duval Patrick appointed Peter to the Board of the Massachusetts Life Sciences Center (“MLSC”) in December 2015. The MLSC is a Massachusetts state agency that is charged with implementing a $1 billion state‑funded life sciences investment
initiative. From 2010-2015, he was also the Life Sciences sector leader for MassChallenge,
the largest business accelerator in the world.